-
1Academic Journal
Συγγραφείς: A. V. Santimov, S. V. Grechanyi, G. A. Novik, А. В. Сантимов, С. В. Гречаный, Г. А. Новик
Πηγή: Rheumatology Science and Practice; Vol 62, No 1 (2024); 109-117 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 109-117 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: генно-инженерные биологические препараты, juvenile idiopathic arthritis, juvenile-onset systemic lupus erythematosus, juvenile primary fibromyalgia, anxiety, depression, psychotherapy, psychopharmacotherapy, biological disease-modifying antirheumatic drugs, ювенильный идиопатический артрит, системная красная волчанка с ювенильным дебютом, ювенильная первичная фибромиалгия, тревога, депрессия, психотерапия, психофармакотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3520/2355; Kostev K, Teichgräber F, Konrad M, Jacob L. Association between chronic somatic conditions and depression in children and adolescents: A retrospective study of 13,326 patients. J Affect Disord. 2019;245:697-701. doi:10.1016/j.jad.2018.11.014; Williams NA, Burnfield JM. Psychological difficulties and parental well-being in children with musculoskeletal problems in the 2011/2012 National Survey of Children’s Health. Rehabil Psychol. 2019;64(1):87-97. doi:10.1037/rep0000251; Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi:10.1038/nri.2015.5; Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640. doi:10.3390/ijms22041640; Davis AM, Rubinstein TB, Rodriguez M, Knight AM. Mental health care for youth with rheumatologic diseases – bridging the gap. Pediatr Rheumatol Online J. 2017;15(1):85. doi:10.1186/s12969-017-0214-9; Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi:10.1016/S0140-6736(07)60363-8; Korte-Bouws GAH, Albers E, Voskamp M, Hendriksen H, de Leeuw LR, Güntürkün O, et al. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression. Pharmaceuticals (Basel). 2019;12(1):9. doi:10.3390/ph12010009; Reda MM, Hosny E, AbuSenna H. Psychiatric morbidity in patients with rheumatoid juvenile arthritis: A SPECT study. Middle East Curr Psychiat. 2011;18(3):132-137. doi:10.1097/01.XME.0000398422.59986.78; Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al. Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford). 2018;57(8):1381-1389. doi:10.1093/rheumatology/key088; El-Najjar AR, Negm MG, El-Sayed WM. The relationship between depression, disease activity and physical function in juvenile idiopathic arthritis patients in Zagazig University Hospitals – Egypt. Egypt Rheumatologist. 2014;36(3):145-150. doi:10.1016/j.ejr.2014.01.001; Tarakci E, Yeldan I, Kaya Mutlu E, Baydogan SN, Kasapcopur O. The relationship between physical activity level, anxiety, depression, and functional ability in children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(11):1415-1420. doi:10.1007/s10067-011-1832-0; Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: Current insights and impact on quality of life, a systematic review. Open Access Rheumatol. 2019;11:237-252. doi:10.2147/OARRR. S174408; Сантимов АВ, Часнык ВГ, Гречаный СВ. Психометрическая оценка хронического болевого синдрома при ювенильном идиопатическом артрите. Педиатр. 2019;10(3):25-30. [Santimov AV, Chasnyk VG, Grechanyi SV. Psychometric assessment of chronic pain syndrome in juvenile idiopathic arthritis. Pediatrician (St. Petersburg). 2019;10(3):25-30 (In Russ.)]. doi:10.17816/PED10325-30; Сантимов АВ, Часнык ВГ, Гречаный СВ. Уровень тревоги и депрессии у детей и подростков с хроническим болевым синдромом (на примере ювенильного идиопатического артрита). Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2019;4-2:78-86. doi:10.31363/2313-7053-2019-4-2-78-86; Зубарева ЕС, Генералова ДД, Сантимов АВ, Новик ГА, Тамразова ОБ, Гречаный СВ. Выявление нарушений психического здоровья при ювенильном идиопатическом артрите с хроническим болевым синдромом. Педиатрия им. Г.Н. Сперанского. 2023;102(4):147-158. doi:10.24110/0031-403X-2023-102-4-147-158; Kyllönen MS, Ebeling H, Kautiainen H, Puolakka K, Vähäsalo P. Psychiatric disorders in incident patients with juvenile idiopathic arthritis – a case-control cohort study. Pediatr Rheumatol Online J. 2021;19(1):105. doi:10.1186/s12969-021-00599-x; Berthold E, Dahlberg A, Jöud A, Tydén H, Månsson B, Kahn F, et al. The risk of depression and anxiety is not increased in individuals with juvenile idiopathic arthritis – results from the SouthSwedish Juvenile Idiopathic Arthritis Cohort. Pediatr Rheumatol Online J. 2022;20(1):114. doi:10.1186/s12969-022-00765-9; Delcoigne B, Horne A, Reutfors J, Askling J. Risk of psychiatric disorders in juvenile idiopathic arthritis: Population- and siblingcontrolled cohort and cross-sectional analyses. ACR Open Rheumatol. 2023;5(5):277-284. doi:10.1002/acr2.11549; Mann CM, Schanberg LE, Wang M, von Scheven E, Lucas N, Hernandez A, et al. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. Qual Life Res. 2020;29(9):2573-2584. doi:10.1007/s11136-020-02513-6; Kısaarslan AP, Çiçek SÖ, Batu ED, Şahin S, Gürgöze MK, Çetinkaya SB, et al. Neuropsychiatric involvement in juvenileonset systemic lupus erythematosus: A multicenter study. Joint Bone Spine. 2023;90(4):105559. doi:10.1016/j.jbspin.2023.105559; Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi:10.1186/s40348-023-00161-7; Donnelly C, Cunningham N, Jones JT, Ji L, Brunner HI, Kashikar-Zuck S. Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus. Lupus. 2018;27(1):124- 133. doi:10.1177/0961203317716317; Каледа МИ, Никишина ИП. Нейропсихические нарушения при системной красной волчанке с ювенильным дебютом. Научно-практическая ревматология. 2020;58(4):437-442. doi:10.47360/1995-4484-2020-437-442; Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ.Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi:10.14412/1995-4484-2020-171-177; Кучинская ЕМ, Яковлева ЮА, Ракова МА, Любимова НА, Суспицын ЕН, Костик ММ. Системная красная волчанка с нейропсихическими проявлениями у ребенка: описание клинического случая и обзор международных рекомендаций по диагностике и лечению. Российский вестник перинатологии и педиатрии. 2021;66(1):98-105. doi:10.21508/1027-4065-2021-66-1-98-105; Кучинская ЕМ, Часнык ВГ, Костик ММ. Системная красная волчанка у детей: применение формализованных методов описания течения и исхода заболевания в ретроспективном исследовании. Педиатр. 2017;8(5):35-43. doi:10.17816/PED8535-43; Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al.; UK JSLE Cohort Study. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus. 2021;30(12):1955-1965. doi:10.1177/09612033211045050; Knight AM, Xie M, Mandell DS. Disparities in psychiatric diagnosis and treatment for youth with systemic lupus erythematosus: Analysis of a national US Medicaid sample. J Rheumatol. 2016;43(7):1427-1433. doi:10.3899/jrheum.150967; Coles ML, Weissmann R, Uziel Y. Juvenile primary fibromyalgia syndrome: Epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis. Pediatr Rheumatol Online J. 2021;19(1):22. doi:10.1186/s12969-021-00493-6; Kashikar-Zuck S, Parkins IS, Graham TB, Lynch AM, Passo M, Johnston M, et al. Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome. Clin J Pain. 2008;24(7):620-626. doi:10.1097/AJP.0b013e31816d7d23; Conte PM, Walco GA, Kimura Y. Temperament and stress response in children with juvenile primary fibromyalgia syndrome. Arthritis Rheum. 2003;48(10):2923-2930. doi:10.1002/art.11244; Kashikar-Zuck S, Cunningham N, Peugh J, Black WR, Nelson S, Lynch-Jordan AM, et al. Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time. Pain. 2019;160(2):433-441. doi:10.1097/j.pain.0000000000001415; Connelly M, Weiss JE. Pain, functional disability, and their association in juvenile fibromyalgia compared to other pediatric rheumatic diseases. Pediatr Rheumatol. 2019;17(1):72. doi:10.1186/s12969-019-0375-9; Weiss JE, Schikler KN, Boneparth AD, Connelly M. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol. 2019;17(1):1-8. doi:10.1186/s12969-019-0356-z; Siegel DM, Janeway D, Baum J. Fibromyalgia syndrome in children and adolescents: Clinical features at presentation and status at follow-up. Pediatrics. 1998;101(3 Pt 1):377-382. doi:10.1542/peds.101.3.377; Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227. doi:10.1001/archinte.160.2.221; Gmuca S, Sherry DD. Fibromyalgia: Treating pain in the juvenile patient. Pediatr Drugs. 2017;19(4):325-338. doi:10.1007/s40272-017-0233-5; Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2(8):416-424. doi:10.1038/ncprheum0245; Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum. 2012;64(1):297-305. doi:10.1002/art.30644; Fisher E, Law E, Dudeney J, Palermo TM, Stewart G, Eccleston C. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2018;9(9):CD003968. doi:10.1002/14651858.CD003968.pub5; Сантимов АВ, Часнык ВГ, Гречаный СВ. Психотерапевтический подход к лечению хронического болевого синдрома при ювенильном идиопатическом артрите и предикторы его эффективности. Психиатрия, психотерапия и клиническая психология. 2022;13(2):138-150. doi:10.34883/PI.2022.13.2.010; Trachtman R, Samuels J, Wojtal E, Feldman BM. Resilience and its associations in children with systemic lupus erythematosus and juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2023;21(1):67. doi:10.1186/s12969-023-00854-3; Ross E, Abulaban K, Kessler E, Cunningham N. Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review. Lupus. 2022;31(7):864-879. doi:10.1177/09612033221094704; Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347-1368. doi:10.1517/14656566.2015.1047343; Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292. doi:10.1002/14651858.CD010292.pub2; Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019;17(1):27. doi:10.1186/s12969-019-0325-6; Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: Lessons from a clinical trial program. Pediatr Rheumatol Online J. 2015;13:27. doi:10.1186/s12969-015-0025-9; Mariutto EN, Stanford SB, Kashikar-Zuck S, Welge JA, Arnold LM. An exploratory, open trial of fluoxetine treatment of juvenile fibromyalgia. J Clin Psychopharmacol. 2012;32(2):293-295. doi:10.1097/JCP.0b013e31824858dc; Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: A systematic review of its efficacy. Rheumatology (Oxford). 2008;47(12):1741-1746. doi:10.1093/rheumatology/ken317; Migliorini F, Maffulli N, Knobe M, Tenze G, Aljalloud A, Colarossi G. Pregabalin administration in patients with fibromyalgia: A Bayesian network meta-analysis. Sci Rep. 2022;12(1):12148. doi:10.1038/s41598-022-16146-x; Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-1344. doi:10.1002/art.22457; Egunsola O, Wylie CE, Chitty KM, Buckley NA. Systematic review of the efficacy and safety of gabapentin and pregabalin for pain in children and adolescents. Anesth Analg. 2019;128(4):811-819. doi:10.1213/ANE.0000000000003936; Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, BhadraBrown P, et al.; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: A randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46. doi:10.1186/s12969-016-0106-4; Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. doi:10.3390/ijms21062194; Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi:10.14412/1995-4484-2019-318-327; Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224-244. doi:10.1038/s41573-021-00368-1; Лисицына ТА, Абрамкин АА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Борисова АБ, и др. Эффективность олокизумаба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования. Научно-практическая ревматология. 2023; 61(2):188-198. doi:10.47360/1995-4484-2023-188-198; Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781-791. doi:10.1007/s00296-019-04251-6; Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016;290:22-25. doi:10.1016/j.jneuroim.2015.11.011; Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia – A controlled cross-sectional study. Cytokine. 2016;84:25-28. doi:10.1016/j.cyto.2016.05.011; Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, et al. Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol. 2013;31(6 Suppl 79):S60-S63.; Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa Al, et al. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: Role of IL-37. J Biol Regul Homeost Agents. 2018;32(2):195-198.; Loncharich MF, Robertson I. Anifrolumab in systemic lupus erythematosus. Drugs Today (Barc). 2023;59(2):53-61. doi:10.1358/dot.2023.59.2.3521876; Алексеева ЕИ, Денисова РВ, Валиева СИ, Бзарова ТМ, Слепцова ТВ, Чомахидзе АМ, и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504. doi:10.15690/vsp.v15i5.1624; Калашникова ЭМ, Раупов РК, Любимова НА, Кучинская ЕМ, Масалова ВВ, Исупова ЕА, и др. Опыт применения ритуксимаба у пациентов с ювенильной системной красной волчанкой: предварительные результаты двуцентрового когортного исследования. Российский вестник перинатологии и педиатрии. 2023;68(1):74-84. doi:10.21508/1027-4065-2023-68-1-74-84; Santimov A, Grom AA. Other biological therapies for pediatric rheumatic diseases. Handbook Syst Autoimmun Dis. 2016;11:503-525. doi:10.1016/B978-0-444-63596-9.00024-4; Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222. doi:10.3389/fmed.2020.00222; Cheng H, Zhang XY, Yang HD, Yu Z, Yan CL, Gao C, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. doi:10.3389/fimmu.2022.911730; Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Relat Outcome Meas. 2019;10:1-7. doi:10.2147/PROM.S134326; Xu Y, Xu JW, Wang YJ, Tung TH, Chien CW. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and metaanalysis of randomised controlled trials. Int Immunopharmacol. 2022;109:108811. doi:10.1016/j.intimp.2022.108811